Загрузка...

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus

BACKGROUND: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. METHODS: We performed a multicenter prospective trial in patients with type 2 diabetes...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Med Res
Главные авторы: Chiba, Yukari, Yamakawa, Tadashi, Tsuchiya, Hirohisa, Oba, Mari, Suzuki, Daisuke, Danno, Hirosuke, Takatsuka, Yoji, Shigematsu, Hiroshi, Kaneshiro, Mizuki, Terauchi, Yasuo
Формат: Artigo
Язык:Inglês
Опубликовано: Elmer Press 2018
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6031245/
https://ncbi.nlm.nih.gov/pubmed/29977423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3464w
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!